Dr. Loyd V. Allen, Jr., PhD, RPh, FACA, a trailblazer in the compounding industry who was highly regarded by students, colleagues and regulatory agencies, passed away on April 23, 2024.

In recognition of National Infertility Awareness Week, April 21-27, PCCA Director of Clinical Services Sara Hover, RPh, FAARM, discusses how fertility is increasingly viewed as an indicator of overall health; how the intertwine of metabolic balance, hormone production and mitochondria impact fertility; as well as a way compounders can help those whose individual needs exceed commercially available medicines.

Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.

Our Profiles in Personalized Medicine highlights Matthew McLachlan, BPharm, MPS, co-owner of O’Hara's Pharmacy 777 Kalamunda in Kalamunda, Western Australia. Matthew shares what motivated him to become a compounding pharmacist, how his pharmacy promotes compounding in their community and more. He and co-owner Andrew Mason, BPharm, MPS, have been proud PCCA members since 2018.

In February, the FDA approved the first and only oral treatment for eosinophilic esophagitis (EoE) that contains the active pharmaceutical ingredient (API) budesonide at a strength of 2 mg/10mL, which may sound familiar to many compounders.1 How does this affect compounders and what other potential options are available to patients?